Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished
PITTSBURGH, Dec. 20, 2023 (GLOBE NEWSWIRE) — Lipella Pharmaceuticals Inc., (Nasdaq:LIPO) (“Lipella,” “our,” “us” or the “Company”), a pioneering, clinical-stage pharmaceutical company, celebrates its first anniversary as a publicly traded entity. Based in Pittsburgh, PA, the Company has made substantial strides over the past year, achieving critical milestones and advancing its pipeline with three clinical indications and two orphan drug designations granted.
Related news for (LIPO)
- Lipella Pharmaceuticals to Present at Zacks SCR Life Sciences Virtual Investor Forum and Report Final Phase 2a Results in Oral Lichen Planus
- Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market
- Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology
- Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development
- Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting